AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
1-Year Est. Return
29.75%
1 Year Est. Return
+29.75%
AUM
$676M
AUM Growth
+$37.5M
(+5.9%)
Holding
109
Top Buys
| 1 | +$33.7M | |
| 2 | +$32M | |
| 3 | +$9.71M | |
| 4 |
Lexeo Therapeutics
LXEO
|
+$8.48M |
| 5 |
Enliven Therapeutics
ELVN
|
+$8.02M |
Top Sells
| 1 | +$19.9M | |
| 2 | +$16.8M | |
| 3 | +$13.3M | |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$8.5M |
| 5 |
INZY
Inozyme Pharma
INZY
|
+$8.47M |
Sector Composition
| 1 | Healthcare | 95.02% |
| 2 | Financials | 0.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
1
DELISTED
Verona Pharma
VRNA
| $57.7M | 7.88% |
610,000
-5,000
|
|
||
2
Insmed
INSM
$35B
| $47.8M | 6.53% |
475,000
+335,000
|
|
||
3
Xenon Pharmaceuticals
XENE
$3.21B
| $34.4M | 4.7% |
1,100,000
-228,175
|
|
||
4
Arcellx
ACLX
$4.82B
| $32.6M | 4.45% |
495,000
-35,000
|
|
||
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $32M | 4.38% |
+250,000
|
|
||
6
Nuvalent
NUVL
$6.67B
| $31.7M | 4.32% |
415,000
-45,000
|
|
||
7
Apogee Therapeutics
APGE
$3.73B
| $30M | 4.1% |
691,899
-459,300
|
|
||
8
Alkermes
ALKS
$5B
| $28.6M | 3.91% |
1,000,000
|
|
||
9
Protagonist Therapeutics
PTGX
$4.82B
| $24.3M | 3.32% |
440,000
+40,000
|
|
||
10
Madrigal Pharmaceuticals
MDGL
$9.78B
| $24.2M | 3.31% |
80,000
|
|
||
11
Teva Pharmaceuticals
TEVA
$22.2B
| $23.5M | 3.2% |
1,400,000
|
|
||
|
12
Lexeo Therapeutics
LXEO
$517M
| $14.4M | 1.97% |
3,589,355
+2,108,474
|
|
||
13
Travere Therapeutics
TVTX
$2.44B
| $14.4M | 1.96% |
970,000
-100,000
|
|
||
14
Establishment Labs
ESTA
$1.37B
| $14.3M | 1.95% |
334,863
+54,863
|
|
||
15
Trevi Therapeutics
TRVI
$1.26B
| $13.9M | 1.89% |
2,534,058
+1,284,058
|
|
||
16
Wave Life Sciences
WVE
$1.24B
| $13M | 1.78% |
2,000,308
+175,308
|
|
||
17
Vera Therapeutics
VERA
$1.99B
| $12.8M | 1.75% |
545,000
+189,857
|
|
||
18
Mineralys Therapeutics
MLYS
$3.38B
| $12.2M | 1.66% |
900,000
-200,000
|
|
||
|
CNTA
19
Centessa Pharmaceuticals
CNTA
$3.09B
| $11.8M | 1.62% |
900,162
-646,500
|
|
||
20
Nurix Therapeutics
NRIX
$757M
| $11M | 1.51% |
967,620
+156,951
|
|
||
21
Rezolute
RZLT
$789M
| $9.81M | 1.34% |
2,200,000
+500,000
|
|
||
22
Ventyx Biosciences
VTYX
$280M
| $9.71M | 1.33% |
+4,536,182
|
|
||
23
Spyre Therapeutics
SYRE
$1.74B
| $9.08M | 1.24% |
606,678
+125,000
|
|
||
|
24
Enliven Therapeutics
ELVN
$1.27B
| $8.02M | 1.1% |
+400,000
|
|
||
25
ProQR Therapeutics
PRQR
$293M
| $7.14M | 0.98% |
3,499,512
+215,000
|
|